Led · Equity · Jul 2025

Kardium developed the Globe® Pulsed Field System, a catheter-based AF treatment featuring a 122-electrode array for rapid pulmonary vein isolation, high-definition mapping, and whole‑atrium ablation with a single catheter. The Globe System showed 78% freedom from atrial arrhythmia at 1 year in paroxysmal AF patients in the pivotal PULSAR study and reported 0% device-related primary safety events. The system is currently restricted to investigational use and has not been approved or cleared for commercial distribution. Kardium plans to use new funding to pursue regulatory approvals, expand manufacturing and production capacity, build a clinical support and commercial team, and run further clinical research for additional applications and indications. The company is privately held, was founded in 2007, and is headquartered in Vancouver, Canada. The recent financing positions Kardium to move toward a commercial launch later this year. Kardium develops the Globe Mapping and Ablation System, a single-catheter solution with a 122-electrode array and advanced software for rapid pulmonary vein isolation, high-definition mapping, and atrial ablation. The company says recent clinical data show freedom from atrial arrhythmia at one year of 84.2% in paroxysmal AF and 80% in persistent AF. Kardium raised US $104 million in a new financing to support completion of its PULSAR clinical study and to pursue regulatory approvals for the Globe System. The financing will also fund growth of manufacturing capacity and expansion of clinical support and commercial teams in preparation for commercial launch. Kardium is a privately held company founded in 2007 and headquartered in Vancouver, Canada. The Globe System remains restricted to investigational use and has not been approved or cleared for commercial distribution. Kardium has developed the Globe Mapping and Ablation System for the treatment of atrial fibrillation. The Globe System uses a sophisticated catheter with a 122-electrode array and advanced software to enable rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium with a single catheter. In the past six months the company secured CE mark approval, launched the Globe System in Europe, and deployed the Globe Positioning System (GPS) 3D mapping and navigation module. The new financing will be used to accelerate commercial growth across Europe and to conduct a clinical study for FDA approval of the Globe System. The financing will also fund clinical studies of a new pulsed field ablation (PFA) version of the Globe System following positive pre-clinical testing. Founded in 2007 and headquartered in Vancouver, Kardium plans to expand activity across European markets and advance its FDA submissions. Kardium develops the Globe® Mapping and Ablation System, a mapping and ablation solution for the treatment of atrial fibrillation. The Globe system pairs a sophisticated catheter with 122 electrodes and advanced software to enable rapid pulmonary vein isolation, high-resolution mapping, and the ability to ablate anywhere in the atrium. Kardium completed successful clinical testing of the Globe system in Switzerland and Germany and plans commercial sales in Europe in 2019. The company will also start a clinical study in the US this year. Kardium was founded in 2007 and is based in Vancouver, British Columbia. It announced a new, undisclosed financing led by funds and accounts advised by T. Rowe Price, which the company said will fund commercial activities in Europe and Canada and support US clinical testing.

Participated · Series C · Apr 2024

Endeavor BioMedicines is a San Diego–based clinical-stage biotechnology company developing medicines aimed at delivering transformational clinical benefits for patients with life-threatening diseases. Its lead candidate, ENV-101, is an inhibitor of the Hedgehog signaling pathway in development for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) and showed preliminary results in a randomized, double-blind, placebo-controlled Phase 2a trial. Endeavor says ENV-101 has the potential to improve lung function and reverse fibrotic processes; the company plans to initiate a Phase 2b trial in IPF and a parallel PPF cohort in 2024, with Phase 2a results to be presented at the ATS International Conference. Its second candidate, ENV-501, is a next-generation anti-HER3 antibody-drug conjugate engineered to minimize off-target toxicity and is planned to enter a Phase 1/2 trial in 2024. The company closed an oversubscribed $132.5 million Series C, including conversion of a $5 million convertible instrument, to advance clinical development of ENV-101 and ENV-501. Leadership states the financing and board support position the company to pursue key clinical milestones in 2024 and beyond. Endeavor BioMedicines is a clinical-stage biotechnology company targeting the core drivers of terminal diseases, including oncology and fibrosis. Its lead program, ENV-101 (taladegib), is an oral small-molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway and has shown clinical efficacy and safety in nearly 200 subjects across six completed studies. The company is pursuing precision, tumor-agnostic approaches for ENV-101 in cancers with oncogenic PTCH1 mutations (found in approximately 2% of cancers) and is enrolling a Phase 2 oncology trial (NCT05199584) as well as a Phase 2 study in idiopathic pulmonary fibrosis (NCT04968574). ENV-201 is an oral ULK1/2 inhibitor designed to block autophagy in KRAS- and STK11-mutated cancers; Endeavor plans to complete IND-enabling studies and advance the program into the clinic within the next year. The firm emphasizes genetically defined patient selection and combination strategies with chemo-, targeted-, and immuno-therapies to overcome resistance. Recently raised capital will be used to advance these pipeline programs toward clinical milestones. Endeavor BioMedicines is developing taladegib, an inhibitor targeting the hedgehog signaling pathway to treat pulmonary disease, specifically idiopathic pulmonary fibrosis (IPF). The company will use its Series A funding to support two Phase 2 clinical trials that will assess whether taladegib can reverse or slow IPF progression. IPF is characterized by lung tissue scarring and has an estimated mean survival of 2–5 years from diagnosis. Endeavor is led by co-founder and CEO John Hood and co-founder and chief science officer Miguel de los Rios. The startup emerged from stealth with a $62 million Series A raised from Omega Funds and Longitude Capital, plus participation from the company’s management team. CEO John Hood previously led Impact Biomedicines, which was acquired by Celgene for up to $7 billion.

Participated · Equity · Apr 2024

Avive Solutions develops the Avive Connect AED, a connected automated external defibrillator, alongside complementary software. The Avive Connect AED emphasizes portability, accessibility and connectivity and is paired with the REALConnect platform to streamline AED ownership and management. Avive also provides an intelligent response platform designed to deliver comprehensive cardiac arrest response capabilities to communities. The company is led by CEO Sameer Jafri and is based in San Francisco. In April 2024 Avive closed a $56.5M Growth Equity financing to support its commercial expansion. The company plans to use the proceeds to accelerate U.S. commercial developments and to expand its team with additional talent. Avive Solutions is a healthcare technology company building a connected automated external defibrillator (AED) paired with a software platform that integrates with public safety and provider ecosystems to address out-of-hospital cardiac arrest (OHCA). The platform connects with 911 Emergency Communications Centers via a partnership with RapidSOS and provides incident data-sharing to close data gaps during cardiac arrest responses. Avive has developed the "4-Minute City" program, which places AEDs strategically across municipalities combined with community training to promote early intervention and equitable outcomes. The company aims to increase survival rates from cardiac arrest and reduce disparities tied to socioeconomic and demographic factors. Led by co-founder and CEO Sameer Jafri and based in San Francisco, Avive closed a $22M Series A to advance its technology-enabled approach to improving OHCA survival rates. Avive Solutions is a San Francisco–based healthcare technology company developing a next-generation AED paired with a first-of-its-kind platform to revolutionize out-of-hospital cardiac arrest response. The company aims to increase SCA survival rates by combining advanced, affordable hardware with data-driven software and integrations into the emergency response ecosystem. Avive emphasizes accessible CPR training features, rapid defibrillation workflows, and a data link to professional first responders. Funding will be used to prepare for commercial launch pending FDA approval and to accelerate platform development and ecosystem integrations. Founded in 2017, Avive has raised over $15 million to date and is in the midst of the FDA review cycle. The company situates its product strategy around shortening time-to-defibrillation to address U.S. out-of-hospital SCA, which accounts for over 350,000 deaths annually and has national average survival rates below 10%. Revive Solutions is a San Francisco-based healthcare technology company developing a next-generation automated external defibrillator and accompanying software aimed at increasing survival from sudden cardiac arrest. The product is described as ultra-portable, easy to maintain, affordable, and simple for bystanders to use effectively. Revive positions its device to address limited AED accessibility caused by bulk, intimidating interfaces, maintenance burdens, and high price points. Proceeds from the recent financing will be used to complete the regulatory submission and pursue commercial launch upon FDA approval. The company emphasizes bringing a modernized, accessible AED to market to improve stagnant survival rates. To date, Revive has raised over $6M.

Participated · Series B · Sep 2023

Awak Technologies is a Singapore-based patient-centric medical technology company led by CEO Suresha Venkataraya. Its core product is an ultra-portable peritoneal dialysis system that enables kidney disease patients to undergo dialysis at home or on the go. The company’s patented technologies regenerate and reconstitute waste dialysis fluid into usable fluid, reducing the amount of dialysis fluid needed by up to 90% and enabling miniaturisation of the machine to fit into a small carry bag. Awak plans to use the recent funding to complete an ongoing human pre-pivotal clinical trial, further enhance its products and portfolio, and advance toward a US-based pivotal trial and eventual US launch. The company has offices in Burbank, California and Bengaluru, India. The Series B financing (over USD$20M) supports these clinical and commercialisation efforts. AWAK Technologies develops the AWAK PD, a wearable, ultra‑portable sorbent‑based peritoneal dialysis device that removes uremic toxins from spent dialysate and reconstitutes used fluid into fresh fluid in real time. The device is lightweight (a couple of kilograms), designed for patient self‑administration without medical supervision and aims to eliminate dependence on large dialysate volumes, continuous water supply and costly water treatment. AWAK completed a first‑in‑human study in October 2018 with no serious adverse events and demonstrated effective waste removal, and the device has received FDA Breakthrough Device Designation. Proceeds from the recent financing will be used to complete a pivotal clinical trial, strengthen R&D, and prepare for manufacturing and commercialisation, with AWAK expecting to initiate a pivotal study in the next 12–18 months while engaging global regulators. The company is headquartered in Singapore with an office in Burbank, California. Financially, AWAK closed an oversubscribed US$40M financing in 2019 — the largest medtech fundraise in Singapore and among the largest in Southeast Asia — bringing total funding since inception to more than US$60M. AWAK Technologies is a Singapore medtech startup focused on developing solutions for patients with end-stage renal disease. Its core work centers on medical technologies aimed at treating or managing end-stage renal failure. The company recently secured an $11.2 million investment led by Accuron MedTech. Accuron MedTech is a division of Accuron Technologies Limited, a wholly‑owned subsidiary of Temasek Holdings. The article does not disclose the financing instrument, participation of additional investors, past rounds, revenues, or other operating metrics. The reported funding represents institutional backing from a Temasek‑linked investor as AWAK advances its medtech efforts.